FONAR (FONR) 10-K 27 Sep 24 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2024	Sep. 18, 2024	Dec. 29, 2023
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	0-10248
Entity Registrant Name	FONAR CORPORATION
Entity Central Index Key	0000355019
Entity Tax Identification Number	11-2464137
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	110 Marcus Drive
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	694-2929
Title of 12(b) Security	Common Stock, $.0001 par value
Trading Symbol	FONR
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 121
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Marcum
Auditor Firm ID	688
Auditor Location	New York, NY
Common Stock [Member]
Entity Common Stock, Shares Outstanding		6,328,294
Common Class B [Member]
Entity Common Stock, Shares Outstanding		146
Common Class C [Member]
Entity Common Stock, Shares Outstanding		382,513
Class A Non Voting Preferred Stock [Member]
Entity Common Stock, Shares Outstanding		313,438

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Current Assets:
Cash and cash equivalents	$ 56,341,193	$ 51,279,707
Short-term investments	136,102	32,799
Accounts receivable – net of allowances for credit losses of $166,049 and $198,593 at June 30, 2024 and 2023, respectively	4,035,336	3,861,512
Medical receivables – net	23,991,533	21,259,262
Management and other fees receivable – net of allowances for credit losses of $12,369,921 and $12,608,567 as of June 30, 2024 and 2023, respectively	41,953,657	35,888,253
Management and other fees receivable – related party medical practices – net of allowances for credit losses of $6,110,399 and $3,989,692 as of June 30, 2024 and 2023, respectively	9,865,061	9,161,870
Inventories	2,715,441	2,569,666
Prepaid expenses and other current assets	1,285,962	1,607,768
Total Current Assets	140,324,285	125,660,837
Accounts receivable – long term	829,473	710,085
Note receivable – related party	581,183	0
Deferred income tax asset	7,223,255	10,041,960
Property and equipment – net	18,708,920	22,146,373
Right-of-use-assets – operating leases	38,427,757	33,068,755
Right-of-use-asset – financing lease	530,348	729,229
Goodwill	4,269,277	4,269,277
Other intangible assets – net	2,870,324	3,431,865
Other assets	481,147	523,506
Total Assets	214,245,969	200,581,887
Current Liabilities:
Current portion of long-term debt	47,002	43,767
Accounts payable	1,855,879	1,579,240
Other current liabilities	7,941,039	5,443,724
Operating lease liabilities – current portion	3,473,674	3,905,484
Financing lease liability – current portion	225,786	217,597
Unearned revenue on service contracts	3,870,229	3,832,184
Customer deposits	443,471	602,377
Total Current Liabilities	17,857,080	15,624,373
Long-Term Liabilities:
Unearned revenue on service contracts	1,174,844	760,242
Deferred income tax liability	371,560	394,758
Due to related party medical practices	92,663	92,663
Operating lease liabilities – net of current portion	37,467,746	32,105,405
Financing lease liability – net of current portion	394,723	620,481
Long-term debt and capital leases, less current portion	66,938	115,075
Other liabilities	32,026	41,750
Total Long-Term Liabilities	39,600,500	34,130,374
Total Liabilities	57,457,580	49,754,747
Commitments and Contingencies
Stockholders’ Equity:
Paid-in capital in excess of par value	180,607,510	182,612,518
Accumulated deficit	(13,623,585)	(24,190,981)
Treasury stock, at cost – 45,081 and 11,463 shares of common stock at June 30, 2024 and 2023, respectively	(1,016,632)	(515,820)
Total Fonar Corporation’s Stockholders’ Equity	165,967,997	157,906,433
Noncontrolling interests	(9,179,608)	(7,079,293)
Total Stockholders’ Equity	156,788,389	150,827,140
Total Liabilities and Stockholders’ Equity	214,245,969	200,581,887
Class A Non Voting Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock value	31	31
Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock value	0	0
Common Stock [Member]
Stockholders’ Equity:
Common stock value	635	647
Common Class B [Member]
Stockholders’ Equity:
Common stock value	0	0
Common Class C [Member]
Stockholders’ Equity:
Common stock value	$ 38	$ 38

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Accounts receivable - net of allowances for credit losses	$ 166,049	$ 198,593
Management and other fees receivable - net of allowances for credit losses	12,369,921	12,608,567
Management and other fees receivable - related party medical practices - net of allowances for credit losses	$ 6,110,399	$ 3,989,692
Treasury stock, shares	45,081	11,463
Class A Non Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	453,000	453,000
Preferred stock, shares issued	313,438	313,438
Preferred stock, shares outstanding	313,438	313,438
Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	567,000	567,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	8,500,000	8,500,000
Common stock, shares issued	6,373,375	6,462,345
Common stock, shares outstanding	6,328,294	6,450,882
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	227,000	227,000
Common stock, shares issued	146	146
Common stock, shares outstanding	146	146
Common Class C [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	567,000	567,000
Common stock, shares issued	382,513	382,513
Common stock, shares outstanding	382,513	382,513

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenues
Patient fee revenue, net of contractual allowances and discounts	$ 33,815,796	$ 29,793,993
Product sales	737,727	731,607
Service and repair fees	7,452,212	7,419,104
Service and repair fees – related parties	139,167	110,000
Management and other fees	48,789,287	48,640,497
Management and other fees – related party medical practices	11,949,900	11,949,900
Total Revenues – Net	102,884,089	98,645,101
Costs and Expenses
Costs related to product sales	1,052,159	852,025
Costs related to service and repair fees	3,577,570	3,033,967
Costs related to service and repair fees – related parties	144,413	44,983
Costs related to patient fee revenue	18,199,579	16,183,166
Costs related to management and other fees	28,626,595	26,975,563
Costs related to management and other fees – related party medical practices	6,143,728	5,807,454
Research and development	1,735,949	1,567,749
Selling, general and administrative expenses	26,868,732	29,390,932
Total Costs and Expenses	86,348,725	83,855,839
Income from Operations	16,535,364	14,789,262
Other Income and (Expenses):
Interest expense	(76,997)	(50,131)
Investment income – related party	25,959	0
Investment income	2,126,439	1,222,176
Other income – related party	576,857	0
Other income (expense)	78,763	(202,720)
Income before provision for income taxes and noncontrolling interests	19,266,385	15,758,587
Provision for Income Taxes	(5,168,968)	(3,632,071)
Net Income	14,097,417	12,126,516
Net Income – Noncontrolling Interests	(3,530,021)	(2,750,740)
Net Income – Attributable to FONAR	10,567,396	9,375,776
Common Stockholders [Member]
Other Income and (Expenses):
Net Income Available to Common Stockholders	$ 9,908,920	$ 8,801,974
Basic Net Income Per Common Share Available to Common Stockholders	$ 1.56	$ 1.35
Diluted Net Income Per Common Share Available to Common Stockholders	$ 1.53	$ 1.32
Weighted Average Basic Shares Outstanding - Common Stockholders	6,350,862	6,539,376
Weighted Average Diluted Shares Outstanding - Common Stockholders	6,478,366	6,666,880
Class A Non Voting Preferred Stockholders [Member]
Other Income and (Expenses):
Net Income Available to Common Stockholders	$ 490,776	$ 427,666
Common Class C [Member]
Other Income and (Expenses):
Net Income Available to Common Stockholders	$ 167,700	$ 146,136
Basic Net Income Per Common Share Available to Common Stockholders	$ 0.44	$ 0.38
Diluted Net Income Per Common Share Available to Common Stockholders	$ 0.44	$ 0.38
Weighted Average Basic Shares Outstanding - Common Stockholders	382,513	382,513
Weighted Average Diluted Shares Outstanding - Common Stockholders	382,513	382,513

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Class A Non Voting Preferred [Member]	Common Stock [Member]	Class C Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Jun. 30, 2022	$ 31	$ 657	$ 38	$ 184,531,535	$ (33,566,757)	$ (675,390)	$ (4,053,833)	$ 146,236,281
Beginning balance, shares at Jun. 30, 2022		6,554,210
Net income					9,375,776		2,750,740	12,126,516
Purchase of treasury shares						(1,759,457)		(1,759,457)
Cancellation of shares		$ (10)		(1,919,017)		1,919,027
Cancellation of shares, shares		(103,328)
Distributions to noncontrolling interests							(5,776,200)	(5,776,200)
Ending balance, value at Jun. 30, 2023	31	$ 647	38	182,612,518	(24,190,981)	(515,820)	(7,079,293)	150,827,140
Ending balance, shares at Jun. 30, 2023		6,450,882
Net income					10,567,396		3,530,021	14,097,417
Purchase of treasury shares						(2,505,832)		(2,505,832)
Cancellation of shares		$ (12)		(2,005,008)		2,005,020
Cancellation of shares, shares		(122,588)
Distributions to noncontrolling interests							(5,630,336)	(5,630,336)
Ending balance, value at Jun. 30, 2024	$ 31	$ 635	$ 38	$ 180,607,510	$ (13,623,585)	$ (1,016,632)	$ (9,179,608)	$ 156,788,389
Ending balance, shares at Jun. 30, 2024		6,328,294

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income	$ 14,097,417	$ 12,126,516
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,596,421	4,540,135
Provision for credit losses	1,882,061	5,513,476
Deferred income tax - net	2,795,507	2,979,550
Amortization on right-of-use assets	4,311,762	4,264,818
Gain on sale of equipment – related party	(581,183)
(Gain)Loss on disposition of fixed assets	(75,411)	213,244
Abandoned patents	225,419	0
Changes in assets and liabilities
Accounts, medical and management fee receivables	(11,676,139)	(8,055,843)
Notes receivable	55,200	(64,532)
Inventories	(145,775)	(209,845)
Prepaid expenses and other current assets	266,606	(438,911)
Other assets	42,359	2,763
Accounts payable	276,639	19,685
Other current liabilities	2,949,962	(2,527,100)
Customer advances	(158,906)	241,132
Operating lease liabilities	(4,541,352)	(3,862,814)
Financing lease liabilities	(217,569)	(210,353)
Other liabilities	(9,724)	(64,791)
NET CASH PROVIDED BY OPERATING ACTIVITIES	14,093,294	14,467,130
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(789,961)	(4,218,084)
Purchase of Short-term investment	(103,303)	(473)
Proceeds from sale of equipment	75,411	0
Cost of patents	(32,885)	(119,571)
NET CASH USED IN INVESTING ACTIVITIES	(850,738)	(4,338,128)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of borrowings and capital lease obligations	(44,902)	(36,615)
Purchase of treasury stock	(2,505,832)	(1,759,457)
Distributions to noncontrolling interests	(5,630,336)	(5,776,200)
NET CASH USED IN FINANCING ACTIVITIES	(8,181,070)	(7,572,272)
NET INCREASE IN CASH AND CASH EQUIVALENTS	5,061,486	2,556,730
CASH AND CASH EQUIVALENTS - BEGINNING OF YEAR	51,279,707	48,722,977
CASH AND CASH EQUIVALENTS - END OF YEAR	$ 56,341,193	$ 51,279,707

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ 10,567,396	$ 9,375,776

DESCRIPTION OF BUSINESS AND LIQ

DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES	NOTE 1 - DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES Description of Business FONAR Corporation (the “Company” or “FONAR”) is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (“MRI”) for the detection and diagnosis of human diseases. In addition to deriving revenues from the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through our service and upgrade programs. FONAR, through its wholly-owned subsidiary Health Management Corporation of America (“HMCA”) provides comprehensive management services to diagnostic imaging facilities. The services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development and implementation of practice growth and marketing strategies. On July 1, 2015, the Company restructured the corporate organization of the management of diagnostic imaging centers segment of our business. The reorganization was structured to more completely integrate the operations of Health Management Corporation of America and HDM. Imperial contributed all of its assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a 24.2 45.8 30.0 546,000 70.8 29.2

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, income taxes and related tax asset valuation allowances, contingencies, and revenue recognition. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company’s operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates. Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost or net realizable value. Property and Equipment Property and equipment procured in the normal course of business is stated at cost less accumulated depreciation. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $ 2,948,000 2,801,000 Schedule of estimated useful life in years for property and equipment Diagnostic equipment 5 13 Research, development and demonstration equipment 3 7 Machinery and equipment 2 7 Furniture and fixtures 3 9 Leasehold improvements 5 10 Building 28 Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. If indicators are present, the Company performs a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group in question to its carrying amount. An impairment loss is recognized if it is determined that the long-lived asset group is not recoverable and is calculated by comparing the discounted future cash flows with the carrying value of the related asset group. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors. Other Intangible Assets 1) Patents and Copyrights Patent and copyrights are professional costs incurred to acquire certain patent and copyrights. Amortization is calculated on the straight-line basis over 15 2) Non-Competition Agreements The non-competition agreements are agreements entered into with past principal owners of entities that the Company had acquired. The non-competition agreements are being amortized on the straight-line basis over the length of the agreement ( 7 3) Customer Relationships Customer relationships represents customer lists acquired in acquisition of prior entities. Amortization is calculated on the straight-line basis over 20 Goodwill Goodwill represents the cost of a business acquisition in excess of the fair value of the net assets acquired. Goodwill is not amortized and is reviewed for impairment annually, or more frequently if facts and circumstances indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount including goodwill. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative test to identify and measure the amount of goodwill impairment loss. The Company compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, goodwill of the reporting unit is considered impaired, and that excess is recognized as a goodwill impairment loss. Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 606, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. As of June 30, 2023, the Company had unearned revenue on service contracts of $3,832,184 of which all was recognized as revenue in the fiscal year ending June 30, 2024. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the “PCs”). As of June 30, 2024, the Company has 22 3 19 84,000 447,000 The Company currently recognizes revenue in accordance with the recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts for the years ended June 30, 2024 and 2023 are summarized in the following table. Schedule of patient fee revenue - net For the Years Ended June 30 2024 2023 Commercial Insurance/ Managed Care $ 4,952,712 $ 4,124,646 Medicare/Medicaid 1,138,176 1,063,846 Workers’ Compensation/Personal Injury 20,673,483 18,670,019 Other 7,051,425 5,935,482 Net Patient Fee Revenue $ 33,815,796 $ 29,793,993 Medical Receivable and Management and Other Fees Receivable Medical Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. Management and Other Fees Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. The Company’s considerations into the estimate of the PC’s fee collection is based on a combination of factors. As each management agreement specifies the Company’s ultimate collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers covering automobile no-fault and workers compensation claims incur longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 67% of the PCs’ 2024 and 2023 net revenues were derived from no-fault and personal injury protection claims. The Company combines an objective and subjective loss-rate methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss rates to pools of receivables with similar risk characteristics (i.e., various insurance payors) and then subjectively adjusting for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant factors. The provision for credit losses for the year ended June 30, 2024 was $ 1,882,061 33,419,219 8,602,561 Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. The account receivable balance for scanner service contracts as of July 1, 2022 was $ 4,335,956 Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives. Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $ 731,000 570,000 Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to certain state net operating losses. A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation. In accordance with ASC 740, “Accounting for Income Taxes”, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. The Company believes there are no uncertain tax positions in prior year’s tax filings and therefore it has not recorded a liability for unrecognized tax benefits. In accordance with ASC 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses. Penalties for the years ended June 30, 2024 and June 30, 2023 were $ 20,444 31,122 Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs. Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2024 and 2023, diluted EPS for common shareholders includes 127,504 Schedule of earnings per share June 30, 2024 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,567,396 $ 9,908,920 $ 167,700 Denominator: Weighted average shares outstanding 6,350,862 6,350,862 382,513 Basic income per common share $ 1.66 $ 1.56 $ 0.44 Diluted Denominator: Weighted average shares outstanding 6,350,862 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,478,366 382,513 Diluted income per common share $ 1.53 $ 0.44 June 30, 2023 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 9,375,776 $ 8,801,974 $ 146,136 Denominator: Weighted average shares outstanding 6,539,376 6,539,376 382,513 Basic income per common share $ 1.43 $ 1.35 $ 0.38 Diluted Denominator: Weighted average shares outstanding 6,539,376 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,666,880 382,513 Diluted income per common share $ 1.32 $ 0.38 Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds. Short-Term Investments Short-term investments include certificates of deposit with original maturities of greater than 90 days. Interest is recorded as earned. Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2024, the Company had cash on deposit of approximately $ 53,883,000 250,000 Related Parties: Net revenues from related parties accounted for approximately 12 12 13 See Note 3 regarding the Company’s concentrations in the healthcare industry. Fair Value of Financial Instruments The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received by selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions. The standard establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring and revaluing fair value. These tiers include, Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Short-term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Such amounts include Certificates of Deposits with original maturities greater than 90 days. These securities are classified as Level 1. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company’s financial instruments are held for purposes other than trading. Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (740) “Improvements to Income Tax Disclosures”, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on our disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures. Recently Adopted Accounting Standards The Company adopted ASU 2016-13, “Financial Instruments – Credit Losses” (Topic 326) “Measurement of Credit Losses on Financial Instruments”, on July 1, 2023, as amended which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology, The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. The Company used a modified retrospective approach, which required a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting in which the standard was effective. The adoption did not have a material effect on the Company’s consolidated financial statements. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on the Company’s consolidated financial statements at the time they become effective.

ACCOUNTS RECEIVABLE, MEDICAL RE

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE	NOTE 3 – ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE Long Term Accounts Receivable Long term accounts receivable balances at June 30, 2024 and June 30, 2023 amounted to $ 829,473 710,085 Schedule of receivables - non current - net 2026 $ 631,415 2027 369,429 2028 87,000 2029 87,000 Total $ 1,174,844 The following represents a summary of allowance for credit losses for the years ended June 30, 2024 and 2023, respectively: Summary of allowance for credit losses Description Balance Additions(Recovery) (1) Deductions Balance Accounts receivable $ 198,593 $ — $ 32,544 $ 166,049 Management and other fees receivable 12,608,567 (238,646 ) — 12,369,921 Management and other fees receivable - related medical practices 3,989,692 2,120,707 — 6,110,399 Notes receivable 777,354 — — 777,354 Balance Balance Description June 30, 2022 Additions Deductions June 30, 2023 Accounts receivable $ 204,597 $ 55,000 $ 61,004 $ 198,593 Management and other fees receivable 16,627,917 4,007,382 8,026,732 12,608,567 Management and other fees receivable - related medical practices 4,686,893 1,451,094 2,148,295 3,989,692 Notes receivable 777,354 — — 777,354 (1) Included in provision for credit losses. Net revenues from management and other fees charged to the related party medical practices accounted for approximately 12 12 Tallahassee Magnetic Resonance Imaging, PA, Stand Up MRI of Boca Raton, PA and Stand Up MRI & Diagnostic Center, PA (all related party medical practices) entered into a guaranty agreement, pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual management agreement. The following table sets forth the number of our facilities for the years ended June 30, 2024 and 2023. Total Facilities Schedule of facilities For the Year Ended June 30, 2024 2023 Total Facilities Owned or Managed (at Beginning of Year) 27 27 Facilities Added by: Internal development 1 1 Managed Facilities Closed — (1 ) Total Facilities Owned or Managed (at End of Year) 28 27

INVENTORIES

INVENTORIES	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4 – INVENTORIES Inventories included in the accompanying consolidated balance sheets consist of: Schedule of inventories As of June 30, 2024 2023 Purchased parts and components $ 2,524,201 $ 2,346,300 Work-in-process 191,240 223,366 Inventories $ 2,715,441 $ 2,569,666

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 5 - PROPERTY AND EQUIPMENT Property and equipment, at cost, less accumulated depreciation and amortization, at June 30, 2024 and 2023, is comprised of: Schedule of property and equipment, at cost, less accumulated depreciation and amortization As of June 30, 2024 2023 Diagnostic equipment $ 33,243,694 $ 33,144,266 Research, development and demonstration equipment 6,199,941 6,199,941 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,742,169 3,714,499 Leasehold improvements 16,312,904 15,650,041 Building 939,614 939,614 62,507,377 61,717,416 Less: Accumulated depreciation and amortization 43,798,457 39,571,043 $ 18,708,920 $ 22,146,373 Depreciation and amortization of property and equipment for the years ended June 30, 2024 and 2023 was $ 4,227,414 4,148,544

OPERATING & FINANCING LEASES

OPERATING & FINANCING LEASES	12 Months Ended
	Jun. 30, 2024
Operating Financing Leases
OPERATING & FINANCING LEASES	NOTE 6 – OPERATING & FINANCING LEASES The Company accounts for its various operating leases in accordance with Accounting Standards Codification (‘ASC’) 842 – Lease, as updated by ASU 2016-02. At the inception of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. Our most common initial term varies in length from 2 to 19 years. Including renewal options negotiated with the landlord, we have a total span of 2 to 16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-to-use lease assets consisted of only office space operating leases. In determining the right-to-use lease assets and liabilities, the Company did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (“IBR”) used to discount the stream of operating lease payments is closely related to the interest rates available to the Company. A reconciliation of operating and financing lease payments undiscounted cash flows to lease liabilities recognized as of June 30, 2024 is as follows: Schedule of reconciliation of operating and financing lease payments Year Ending June 30, Operating Lease Payments Financing Lease Payments 2025 $ 5,895,014 $ 244,343 2026 5,561,968 244,343 2027 5,226,352 162,897 2028 5,194,655 — 2029 4,865,285 — Thereafter 29,295,110 — Present value discount (15,096,964 ) (31,074 ) Total lease liability $ 40,941,420 $ 620,509 Weighted Average Remaining Lease Term Schedule of weighted average remaining lease term Operating leases - years 11.0 Finance lease - years 2.6 Weighted Average Discount Rate Operating leases 6.4 % Finance lease 3.6 % The components of lease expense were as follows: Schedule of components of lease expense For Year Ended June 30, 2024 2023 Operating lease cost $ 5,685,008 $ 5,887,390 Finance lease cost: Depreciation of leased equipment $ 198,881 $ 198,881 Interest on lease liabilities 26,534 35,833 Total finance lease cost $ 225,415 $ 234,714 Supplemental cash flow information related to leases was as follows: Schedule of supplemental cash flow information related to leases For Year Ended June 30, Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 6,363,561 $ 5,577,578 Financing cash flows from financing leases $ 244,344 $ 244,344 Right-of-use and equipment assets obtained in exchange for lease obligations: Operating leases $ 3,715,138 $ 2,902,584

OTHER INTANGIBLE ASSETS

OTHER INTANGIBLE ASSETS	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER INTANGIBLE ASSETS	NOTE 7 - OTHER INTANGIBLE ASSETS Other intangible assets, net of accumulated amortization, at June 30, 2024 and 2023, are comprised of: Schedule of other intangible assets, net of accumulated amortization As of June 30, 2024 2023 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 5,259,811 5,452,345 Non-competition agreements 4,150,000 4,150,000 Customer relationships 3,900,000 3,900,000 20,314,658 20,507,192 Less: Accumulated amortization 17,444,334 17,075,327 $ 2,870,324 $ 3,431,865 The estimated amortization of other intangible assets for the five years ending June 30, 2029 and thereafter is as follows: Schedule of other intangible assets Total Patents and Copyrights Customer Relationships 2025 $ 351,882 $ 151,882 $ 200,000 2026 339,179 139,179 200,000 2027 326,502 126,502 200,000 2028 320,232 120,232 200,000 2029 313,052 113,052 200,000 Thereafter 1,219,477 505,310 714,167 Other intangible assets - net $ 2,870,324 $ 1,156,157 $ 1,714,167 The weighted average amortization period for other intangible assets is 9.9 Information related to the above intangible assets for the years ended June 30, 2024 and 2023 is as follows: Schedule of other intangible assets For the Year-ended June 30, 2024 2023 Balance – Beginning of Year $ 3,431,865 $ 3,703,885 Amounts capitalized 32,885 119,571 Patents written off (225,419 ) — Amortization (369,007 ) (391,591 ) Balance – End of Year $ 2,870,324 $ 3,431,865 Amortization of patents and copyrights for the years ended June 30, 2024 and 2023 amounted to $ 169,007 191,591 Amortization of customer relationships for the years ended June 30, 2024 and 2023 amounted to $ 200,000 200,000

CAPITAL STOCK

CAPITAL STOCK	12 Months Ended
	Jun. 30, 2024
Capital Stock
CAPITAL STOCK	NOTE 8 - CAPITAL STOCK Common Stock Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock. Class B Common Stock Class B common stock is convertible into shares of common stock on a one-for-one basis. Class B common stock has 10 votes per share. 146 Class C Common Stock The Class C common stock has 25 votes per share one vote per share for the common stock. The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock. Class C common stock is convertible into shares of common stock on a three-for-one basis. Class A Non-Voting Preferred Stock On April 3, 1995, the stockholders ratified a proposal consisting of the creation of a new class of Class A non-voting preferred stock with special dividend rights and the declaration of a stock dividend on the Company’s common stock consisting of one share of Class A non-voting preferred stock for every five shares of common stock. The stock dividend was payable to holders of common stock on October 20, 1995. Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares. The Class A non-voting preferred stock is entitled to a special dividend equal to 3-1/4% of the first $10 million, 4-1/2% of the next $20 million and 5-1/2% on amounts in excess of $30 million of the amount of any cash awards or settlements received by the Company in connection with the enforcement of five of the Company’s patents in its patent lawsuits, less the revised special dividend payable on the common stock with respect to one of the Company’s patents. The Class A non-voting preferred stock participates on an equal per share basis with the common stock in any dividends declared and ranks equally with the common stock on distribution rights, liquidation rights and other rights and preferences (other than the voting rights). Stock Bonus Plans On April 23, 2010, the Board approved the 2010 Stock Bonus Plan. The plan entitles the Company to reserve 2,000,000 2,000,000 450,177 0 Treasury Stock On September 13, 2022, the Company adopted a stock repurchase plan. The plan has no expiration date and cannot determine the number of shares which will be repurchased. On September 26, 2022, the Board of Directors has approved up to $ 9 The Company utilizes the cost method of accounting to value the treasury stock when repurchasing stock. Under this method, the shares are valued at the price paid and recorded to treasury stock. When the treasury stock is cancelled, the par value of the stock is reduced and the additional paid in capital is reduced for the remaining value based upon the original stock sale. For the year ended June 30, 2024, the Company purchased 156,206 2,505,832 122,588 2,005,020 103,148 1,759,457 103,328 1,919,027

CONTROLLING AND NONCONTROLLING

CONTROLLING AND NONCONTROLLING INTERESTS	12 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
CONTROLLING AND NONCONTROLLING INTERESTS	NOTE 9 – CONTROLLING AND NONCONTROLLING INTERESTS On February 13, 2013, the Company entered into an agreement with outside investors to acquire a 50.5% controlling interest in a newly formed limited liability company, Health Diagnostics Management LLC (HDM). According to the February 13, 2013, LLC operating agreement of HDM there are two classes of members; Class A members and one Class B member. The Class A members have an ownership interest of 49.5 50.5 20,200,000 19,800,000 On March 5, 2013, HDM purchased from Health Diagnostics, LLC (“HD”) and certain of its subsidiaries, a business managing twelve ( 12 2 1.5 35.9 4.1 On January 8, 2015, the Company purchased 20 4,971,094 60.4 546,000 70.8 29.2 The amount of each class of HDM members’ equity as of June 30, 2024 and 2023 is as follows: Schedule of HDM members equity June 30, 2024 June 30, 2023 Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity ($ 7,079,293 ) $ 54,781,813 ($ 4,053,833 ) $ 50,292,073 Share of Net Income $ 3,530,021 $ 20,705,681 $ 2,750,740 $ 18,513,540 Buyout of noncontrolling interests — — — — Distributions ($ 5,630,336 ) $ (13,669,664 ) ($ 5,776,200 ) $ (14,023,800 ) Ending Members’ Equity ($ 9,179,608 ) $ 61,817,830 ($ 7,079,293 ) $ 54,781,813

LONG-TERM DEBT, NOTES PAYABLE A

LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	12 Months Ended
	Jun. 30, 2024
Long-term Debt Notes Payable And Capital Leases
LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES	NOTE 10 - LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES Long-term debt, notes payable and capital leases consist of the following: Schedule of long-term debt, notes payable and capital leases 2024 2023 Note payable requiring monthly payments of interest at a rate of 7 240 4,472 October 2026 310,827 $ 113,940 $ 158,842 The revolving credit note was extended to November 14, 2024. The Company can borrow up to $ 10,000,000 8.5 — — 113,940 158,842 Less: Current portion 47,002 43,767 $ 66,938 $ 115,075 The maturities of debt over the next three years are as follows: Schedule of maturities of long-term debt Years Ending June 30, 2025 $ 47,002 2026 50,448 2027 16,490 Long-Term Debt Over Five Years and Thereafter $ 113,940

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 11 - INCOME TAXES The Company has recorded a deferred tax asset of $ 7,223,255 371,560 1,323,000 4,516,000 618,000 2,746,000 The Company files corporate income tax returns in the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal, state and local income tax examinations by tax authorities for years prior to 2020. Future ownership changes as determined under Section 382 of the Internal Revenue code could further limit the utilization of net operating loss carryforwards. As of June 30, 2024, no such changes in ownership have occurred. The Inflation Reduction Act (“IRA”) was enacted on August 16, 2022. The IRA includes provisions imposing a 1 15 The valuation allowance for deferred tax assets decreased during the year ended June 30, 2024, by approximately $ 171,000 78,000 Components of the provision for income taxes are as follows: Schedule of components of the provision for income taxes Years Ended June 30, Current: 2024 2023 Federal $ 429,873 $ — State 1,943,588 652,521 Subtotal 2,373,461 652,521 Deferred: Federal deferred taxes 2,585,515 2,770,980 State deferred taxes 209,992 208,570 Subtotal 2,795,507 2,979,550 Provision (Benefit) for Income Taxes - Net $ 5,168,968 $ 3,632,071 A reconciliation of the federal statutory income tax rate to the Company’s effective tax rate as reported is as follows: Schedule of reconciliation of federal statutory income tax rate to company’s effective tax rate Years Ended June 30, 2024 2023 Taxes at federal statutory rate 21.0 % 21.0 % State and local income taxes (benefit), net of federal benefit 7.1 % 5.1 % Non-controlling interest (5.3 )% (4.6 )% Expiration of tax credits 2.2 % 2.8 % Return to provision adjustments — % (2.3 )% Change in the valuation allowance (0.2 )% (0.5 )% Other 2.0 % 1.5 % Effective income tax rate 26.8 % 23.0 % As of June 30, 2024, the Company utilized all Federal net operating loss (“NOL”) carryforwards as compared to NOL’s of approximately $9,110,000 as of June 30, 2023. The utilization of certain of the NOLs is limited by separate return limitation year rules pursuant to Section 1502 of the Internal Revenue Code. The Company has, for federal income tax purposes, research and development tax credits and investments tax credits carryforwards aggregating $ 1,323,000 Significant components of the Company’s deferred tax assets and liabilities at June 30, 2024 and 2023 are as follows: Schedule of company’s deferred tax assets and liabilities June 30, 2024 2023 Deferred tax assets: Allowance for credit losses $ 3,969,819 $ 3,360,809 Non-deductible accruals 758,700 707,400 Net operating carryforwards 396,092 2,768,844 Tax credits 1,323,018 2,981,214 Capitalized research and development 747,407 369,675 Right of use assets and lease liabilities 114,116 112,938 Inventories 106,879 105,310 Deferred Tax Assets - gross 7,416,031 10,406,190 Valuation allowance (192,776 ) (364,230 ) Total deferred tax assets 7,223,255 10,041,960 Property and equipment and depreciation (267,124 ) (151,007 ) Intangibles (104,436 ) (243,751 ) Total deferred tax liabilities (371,560 ) (394,758 ) Net deferred tax asset $ 6,851,695 $ 9,647,202

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	12 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
OTHER CURRENT LIABILITIES	NOTE 12 - OTHER CURRENT LIABILITIES Included in other current liabilities are the following: Schedule of other current liabilities June 30, 2024 2023 Accrued salaries, commissions and payroll taxes $ 4,677,690 $ 4,413,044 Sales tax payable 197,317 193,041 State income taxes payable 1,461,336 48,353 Legal and other professional fees 11,207 11,207 Accounting fees 119,800 100,000 Self-funded health insurance reserve 121,445 100,971 Accrued interest and penalty 3,534 3,534 Other 1,348,710 573,574 Other current liabilities $ 7,941,039 $ 5,443,724

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 - COMMITMENTS AND CONTINGENCIES Leases The Company rents its operating facilities and certain equipment, pursuant to operating lease agreements expiring at various dates through November 2033. The leases for certain facilities contain escalation clauses relating to increases in real property taxes as well as certain maintenance costs. Rent expense for operating leases approximated $ 5,685,000 5,887,000 The Company received approval from the Suffolk County Industrial Development Agency on February 29, 2016 of a 50 440,000 Employee Benefit Plans The Company has a non-contributory 401(k) Plan (the “401(k) Plan”). The 401(k) Plan covers all non-union employees who are at least 21 years of age with no minimum service requirements. There were $ 0 36,523 The stockholders of the Company approved the 2000 Employee Stock Purchase Plan (“ESPP”) at the Company’s annual stockholders’ meeting in April 2000. The ESPP provides for eligible employees to acquire common stock of the Company at a discount, not to exceed 15%. This plan has not been put into effect as of June 30, 2024. Other Matters The Company is subject to other legal proceedings and claims arising from the ordinary course of its business, including personal injury, customer contract and employment claims besides the claim above. In the opinion of management, and with consultation with legal counsel, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated financial position or results of operations of the Company. The Company maintains a self-funded health insurance program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims to $ 110,000 121,000 101,000 The Company regularly analyzes its reserves for incurred but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical paid claims, average lags between the claims’ incurred date, reported dates and paid dates, and the frequency and severity of claims. There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense once a probable amount is known. There were no significant adjustments recorded in the years covered by this report.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Jun. 30, 2024
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 14 - SUPPLEMENTAL CASH FLOW INFORMATION During the years ended June 30, 2024 and 2023 the Company paid $ 76,997 50,132 During the years ended June 30, 2024 and 2023 the Company paid $ 507,139 1,439,507

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 15 – RELATED PARTY TRANSACTIONS On December 31, 2023, the Company entered into an agreement with Magnetic Resonance Management, LLC (“MRM”) for the sale of a MRI scanner. MRM is owned by the CEO and President of the Company. The sales price of the equipment was $ 576,857 9 576,857 Bensonhurst MRI Limited Partnership (“Bensonhurst”), in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum. On February 1, 2024, Bensonhurst entered into a second contract with the Company for the service and maintenance of a High-Field MRI Scanner for a price of $70,000 per annum. Also, during fiscal year ended June 30, 2024, the Company charged Bensonhurst MRI Limited Partnership $190,362 for reimbursable salaries and marketing expenses. The CEO and President of the Company was a minority owner of a billing company, which performs billing and collection services with respect to No-Fault and Workers’ Compensation claims of the Company’s clients. The Company terminated this agreement on January 1, 2021. On June 1, 2017, the Company had also entered into a one year renewable agreement to provide IT services to the billing company for a monthly fee of $ 23,884 Radian Healthcare Management, LLC (“Radian”), which is owned by the son-in-law of the CEO and President of the Company provided the Company with personnel recruitment of 32 new employees at a fee of approximately $200,000 during the fiscal year ended June 30, 2024.

SEGMENT AND RELATED INFORMATION

SEGMENT AND RELATED INFORMATION	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT AND RELATED INFORMATION	NOTE 16 - SEGMENT AND RELATED INFORMATION The Company provides segment data in accordance with the provisions of ASC 280, “Disclosures about Segments of an Enterprise and Related Information”. The Company operates in two industry segments - manufacturing and the servicing of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments are the same as those described in the summary of significant accounting policies. All intersegment sales are market-based. The Company evaluates performance based on income or loss from operations. Summarized financial information concerning the Company’s reportable segments is shown in the following table: Manufacturing and Servicing of Medical Equipment [Member] Management of Diagnostic Imaging Center [Member] Schedule of summarized segment financial information Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2024: Equipment Center Totals Net revenues from external customers $ 8,329,106 $ 94,554,983 $ 102,884,089 Intersegment net revenues * $ 1,073,333 $ — $ 1,073,333 (Loss) Income from operations $ (6,958,012 ) $ 23,493,376 $ 16,535,364 Depreciation and amortization $ 238,802 $ 4,357,619 $ 4,596,421 Total identifiable assets $ 30,360,188 $ 183,885,781 $ 214,245,969 Capital expenditures $ 32,885 $ 789,961 $ 822,846 Fiscal 2023: Net revenues from external customers $ 8,260,711 $ 90,384,390 $ 98,645,101 Intersegment net revenues * $ 985,833 $ — $ 985,833 (Loss) Income from operations $ (5,875,126 ) $ 20,664,388 $ 14,789,262 Depreciation and amortization $ 263,720 $ 4,276,415 $ 4,540,135 Total identifiable assets $ 30,892,807 $ 170,153,612 $ 201,046,419 Capital expenditures $ 119,571 $ 4,218,084 $ 4,337,655 * Amounts eliminated in consolidation Export Product Sales The Company’s areas of operations are principally in the United States. The Company had export sales of medical equipment amounting to 0.2 14.1 The foreign product sales, as a percentage of product sales to unrelated parties, were made to customers in the following countries: Schedule of export product sales For the Years Ended June 30 2024 2023 Canada 0.2 % 8.5 % Germany — 4.9 % United Arab Emirates — 0.7 % 0.2 % 14.1 % Foreign Service and Repair Fees The Company’s areas of service and repair are principally in the United States. The Company had foreign revenues of service and repair of medical equipment amounting to 7.4 6.4 Foreign Service and Repair Fees Schedule of export service revenues For the Years Ended June 30, 2024 2023 Puerto Rico 1.9 % 1.5 % Switzerland 0.3 0.3 Germany 2.0 1.6 England 0.7 0.6 United Arab Emirates 0.3 0.1 Dominican Republic 1.2 0.5 Canada — 0.6 Greece 0.3 0.3 Australia 0.7 0.9 7.4 % 6.4 % The Company does not have any material assets outside of the United States.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 17 – SUBSEQUENT EVENTS The Company evaluates events that have occurred after the balance sheet date, but before the consolidated financial statements are issued. As of September 18, 2024, the Company repurchased 19,914 340,933

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships. The operating activities of subsidiaries are included in the accompanying consolidated statements from the date of acquisition. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The most significant estimates relate to receivable allowances, income taxes and related tax asset valuation allowances, contingencies, and revenue recognition. In addition, healthcare industry reforms and reimbursement practices will continue to impact the Company’s operations and the determination of contractual and other allowance estimates. Actual results could differ from those estimates.
Inventories	Inventories Inventories consist of purchased parts, components and supplies, as well as work-in-process, and are stated at the lower of cost or net realizable value.
Property and Equipment	Property and Equipment Property and equipment procured in the normal course of business is stated at cost less accumulated depreciation. Property and equipment purchased in connection with an acquisition is stated at its estimated fair value, generally based on an appraisal. Property and equipment is being depreciated for financial accounting purposes using the straight-line method over their estimated useful lives. Leasehold improvements are being amortized over the shorter of the useful life or the remaining lease term. Upon retirement or other disposition of these assets, the cost and related accumulated depreciation of these assets are removed from the accounts and the resulting gains or losses are reflected in the results of operations. Expenses for maintenance and repairs are charged to operations. Renewals and betterments are capitalized. Maintenance and repair expenses totaled approximately $ 2,948,000 2,801,000 Schedule of estimated useful life in years for property and equipment Diagnostic equipment 5 13 Research, development and demonstration equipment 3 7 Machinery and equipment 2 7 Furniture and fixtures 3 9 Leasehold improvements 5 10 Building 28
Long-Lived Assets	Long-Lived Assets The Company periodically assesses the recoverability of long-lived assets, including property and equipment and intangibles, other than goodwill, when events or changes in circumstances indicate that the carrying value of long-lived assets may not be recoverable. If indicators are present, the Company performs a recoverability test by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group in question to its carrying amount. An impairment loss is recognized if it is determined that the long-lived asset group is not recoverable and is calculated by comparing the discounted future cash flows with the carrying value of the related asset group. In performing this analysis, management considers such factors as current results, trends, and future prospects, in addition to other economic factors.
Other Intangible Assets	Other Intangible Assets 1) Patents and Copyrights Patent and copyrights are professional costs incurred to acquire certain patent and copyrights. Amortization is calculated on the straight-line basis over 15 2) Non-Competition Agreements The non-competition agreements are agreements entered into with past principal owners of entities that the Company had acquired. The non-competition agreements are being amortized on the straight-line basis over the length of the agreement ( 7 3) Customer Relationships Customer relationships represents customer lists acquired in acquisition of prior entities. Amortization is calculated on the straight-line basis over 20
Goodwill	Goodwill Goodwill represents the cost of a business acquisition in excess of the fair value of the net assets acquired. Goodwill is not amortized and is reviewed for impairment annually, or more frequently if facts and circumstances indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount including goodwill. If it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company performs a quantitative test to identify and measure the amount of goodwill impairment loss. The Company compares the fair value of the reporting unit with its carrying amount. If the carrying amount exceeds fair value, goodwill of the reporting unit is considered impaired, and that excess is recognized as a goodwill impairment loss.
Revenue Recognition	Revenue Recognition Revenue on sales contracts for scanners, included in “product sales” in the accompanying consolidated statements of operations, is recognized under the percentage-of-completion method in accordance with FASB ASC 606, “Revenue Recognition – Construction-Type and Production-Type Contracts”. The Company manufactures its scanners under specific contracts that provide for progress payments. Production and installation take approximately three to six months. Revenue on scanner service contracts is recognized on the straight-line method over the related contract period, usually one year. As of June 30, 2023, the Company had unearned revenue on service contracts of $3,832,184 of which all was recognized as revenue in the fiscal year ending June 30, 2024. Revenue from product sales (upgrades and supplies) is recognized upon shipment. Revenue under management contracts is recognized based upon contractual agreements for management services rendered by the Company primarily under various long-term agreements with various medical providers (the “PCs”). As of June 30, 2024, the Company has 22 3 19 84,000 447,000 The Company currently recognizes revenue in accordance with the recognition accounting standard issued by the Financial Accounting Standards Board (“FASB”) and codified in the ASC as topic 606 (“ASC 606”). The revenue recognition standard in ASC 606 outlines a single comprehensive model for recognizing revenue as performance obligations, defined in a contract with a customer as goods or services transferred to the customer in exchange for consideration, are satisfied. The standard also requires expanded disclosures regarding the Company’s revenue recognition policies and significant judgments employed in the determination of revenue. The Company’s revenues generally relate to net patient fees received from various payers and patients themselves under contracts in which our performance obligations are to provide diagnostic services to the patients. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. Our performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and generally provide for payments based upon predetermined rates per diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The Company’s patient fee revenues, net of contractual allowances and discounts for the years ended June 30, 2024 and 2023 are summarized in the following table. Schedule of patient fee revenue - net For the Years Ended June 30 2024 2023 Commercial Insurance/ Managed Care $ 4,952,712 $ 4,124,646 Medicare/Medicaid 1,138,176 1,063,846 Workers’ Compensation/Personal Injury 20,673,483 18,670,019 Other 7,051,425 5,935,482 Net Patient Fee Revenue $ 33,815,796 $ 29,793,993
Medical Receivable and Management and Other Fees Receivable	Medical Receivable and Management and Other Fees Receivable Medical Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. Management and Other Fees Receivable Management fees receivable is related to management fees outstanding from the related and non related PCs under management agreements. The Company has established a current expected credit loss (“CECL”) to address the risk that a portion of the contractually obligated management fees receivable from the PCs may not be paid. The PC’s may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected fees from third-party payers and patients. The Company’s management fees are collateralized, individually and collectively, by the assets of the PCs. The CECL is determined based on the difference between the management fee receivable and the current amount of outstanding fees estimated to be collected by the PCs. The Company’s considerations into the estimate of the PC’s fee collection is based on a combination of factors. As each management agreement specifies the Company’s ultimate collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers covering automobile no-fault and workers compensation claims incur longer payment cycles and rigorous informational requirements and certain other disallowed claims. Approximately 67% of the PCs’ 2024 and 2023 net revenues were derived from no-fault and personal injury protection claims. The Company combines an objective and subjective loss-rate methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss rates to pools of receivables with similar risk characteristics (i.e., various insurance payors) and then subjectively adjusting for current and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulation. The Company also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant factors. The provision for credit losses for the year ended June 30, 2024 was $ 1,882,061 33,419,219 8,602,561
Accounts Receivable	Accounts Receivable Credit risk with respect to the Company’s accounts receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product sales contract is entered into or service and repair fees are provided. The account receivable balance for scanner service contracts as of July 1, 2022 was $ 4,335,956
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred. The costs of equipment that are acquired or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred. Advertising expense approximated $ 731,000 570,000
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which temporary differences become deductible or when such net operating losses can be utilized. The Company considers projected future taxable income, the regulatory environment of the industry, and tax planning strategies in making this assessment. At present, the Company believes that it is more likely than not that the benefits from certain deferred tax asset carryforwards, will not all be fully realized. In recognition of this inherent risk, a valuation allowance was established for the partial value of the deferred tax asset, which principally related to certain state net operating losses. A valuation allowance will be maintained until sufficient positive evidence exists to support the reversal of the remainder of the valuation. In accordance with ASC 740, “Accounting for Income Taxes”, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. The Company believes there are no uncertain tax positions in prior year’s tax filings and therefore it has not recorded a liability for unrecognized tax benefits. In accordance with ASC 740, interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as “Interest expense, net. Penalties if incurred would be recognized as a component of “Selling, general and administrative” expenses. Penalties for the years ended June 30, 2024 and June 30, 2023 were $ 20,444 31,122
Customer Advances	Customer Advances Cash advances and progress payments received on sales orders are reflected as customer advances until such time as revenue recognition occurs.
Earnings Per Share	Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. In accordance with ASC topic 260-10, “Participating Securities and the Two-Class Method”, the Company used the Two-Class method for calculating basic earnings per share and applied the if converted method in calculating diluted earnings per share for the years ended June 30, 2024 and 2023. Diluted EPS reflects the potential dilution from the exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during the period. For the years ended June 30, 2024 and 2023, diluted EPS for common shareholders includes 127,504 Schedule of earnings per share June 30, 2024 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,567,396 $ 9,908,920 $ 167,700 Denominator: Weighted average shares outstanding 6,350,862 6,350,862 382,513 Basic income per common share $ 1.66 $ 1.56 $ 0.44 Diluted Denominator: Weighted average shares outstanding 6,350,862 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,478,366 382,513 Diluted income per common share $ 1.53 $ 0.44 June 30, 2023 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 9,375,776 $ 8,801,974 $ 146,136 Denominator: Weighted average shares outstanding 6,539,376 6,539,376 382,513 Basic income per common share $ 1.43 $ 1.35 $ 0.38 Diluted Denominator: Weighted average shares outstanding 6,539,376 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,666,880 382,513 Diluted income per common share $ 1.32 $ 0.38
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents includes cash on hand, cash in banks, investments in certificates of deposit with original maturities of 90 days or less, and money market funds.
Short-Term Investments	Short-Term Investments Short-term investments include certificates of deposit with original maturities of greater than 90 days. Interest is recorded as earned.
Concentration of Credit Risk	Concentration of Credit Risk Cash: The Company maintains its cash and cash equivalents with various financial institutions, which exceed federally insured limits throughout the year. At June 30, 2024, the Company had cash on deposit of approximately $ 53,883,000 250,000 Related Parties: Net revenues from related parties accounted for approximately 12 12 13 See Note 3 regarding the Company’s concentrations in the healthcare industry.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures fair value in accordance with ASC 820-10, “Fair Value Measurements and Disclosures”. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received by selling an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions. The standard establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring and revaluing fair value. These tiers include, Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value: Cash and cash equivalents: The carrying amount approximates fair value because of the short-term maturity of those instruments. Short-term investments: The carrying amount approximates fair value because of the short-term maturity of those instruments. Such amounts include Certificates of Deposits with original maturities greater than 90 days. These securities are classified as Level 1. Receivable and accounts payable: The carrying amounts approximate fair value because of the short maturity of those instruments. Notes receivable: The carrying amount approximates fair value because the discounted present value of the cash flow generated by the parties approximates the carrying value of the amounts due to the Company. Long-term debt and notes payable: The carrying amounts of debt and notes payable approximate fair value due to the length of the maturities, the interest rates being tied to market indices and/or due to the interest rates not being significantly different from the current market rates available to the Company. All of the Company’s financial instruments are held for purposes other than trading.
Recent Accounting Standards	Recent Accounting Standards In December 2023, The Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (740) “Improvements to Income Tax Disclosures”, which requires the annual financial statements to include consistent categories and great disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company’s annual reporting beginning after December 15, 2024, with early adoption permitted, and should be applied on a prospective basis, with a retrospective option. The Company is currently evaluating the effect that the adoption of ASU 2023-09 will have on our disclosures. In November 2023, FASB issued ASU 2023-07, “Segment Reporting (Topic 280)”, which is intended to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The amendments require disclosure of significant segment expenses regularly provided to the chief operating decision maker (CODM) as well as other segment items, extended certain annual disclosures to interim periods, clarify the applicability to single reportable segment entities, permit more than one measure of profit or loss to be reported under certain conditions, and require disclosure of the title and position of the CODM. The effective date for public entities is for fiscal years beginning after December 15, 2023 and interim periods with fiscal years beginning after December 15, 2024. The Company is expected to adopt the new disclosures as required and are currently evaluating the impact on the related disclosures.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards The Company adopted ASU 2016-13, “Financial Instruments – Credit Losses” (Topic 326) “Measurement of Credit Losses on Financial Instruments”, on July 1, 2023, as amended which replaces the incurred loss methodology with an expected loss methodology that is referred to as the current expected credit loss (CECL) methodology, The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized cost, including loan receivables and held-to-maturity debt securities. It also applies to off-balance sheet credit exposures not accounted for as insurance (loan commitments, standby letters of credit, financial guarantees, and other similar instruments) and net investments in leases recognized by a lessor in accordance with Topic 842 on leases. The Company used a modified retrospective approach, which required a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting in which the standard was effective. The adoption did not have a material effect on the Company’s consolidated financial statements. FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of June 30, 2024 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected the Company’s financial accounting measures or disclosures had they been in effect during 2024 or 2023, and it does not believe that any of those standards will have a significant impact on the Company’s consolidated financial statements at the time they become effective.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Schedule of estimated useful life in years for property and equipment	Schedule of estimated useful life in years for property and equipment Diagnostic equipment 5 13 Research, development and demonstration equipment 3 7 Machinery and equipment 2 7 Furniture and fixtures 3 9 Leasehold improvements 5 10 Building 28
Schedule of patient fee revenue - net	Schedule of patient fee revenue - net For the Years Ended June 30 2024 2023 Commercial Insurance/ Managed Care $ 4,952,712 $ 4,124,646 Medicare/Medicaid 1,138,176 1,063,846 Workers’ Compensation/Personal Injury 20,673,483 18,670,019 Other 7,051,425 5,935,482 Net Patient Fee Revenue $ 33,815,796 $ 29,793,993
Schedule of earnings per share	Schedule of earnings per share June 30, 2024 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 10,567,396 $ 9,908,920 $ 167,700 Denominator: Weighted average shares outstanding 6,350,862 6,350,862 382,513 Basic income per common share $ 1.66 $ 1.56 $ 0.44 Diluted Denominator: Weighted average shares outstanding 6,350,862 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,478,366 382,513 Diluted income per common share $ 1.53 $ 0.44 June 30, 2023 Basic Total Common Stock Class C Common Stock Numerator: Net income available to common stockholders $ 9,375,776 $ 8,801,974 $ 146,136 Denominator: Weighted average shares outstanding 6,539,376 6,539,376 382,513 Basic income per common share $ 1.43 $ 1.35 $ 0.38 Diluted Denominator: Weighted average shares outstanding 6,539,376 382,513 Class C Common Stock 127,504 — Total Denominator for diluted earnings per share 6,666,880 382,513 Diluted income per common share $ 1.32 $ 0.38

ACCOUNTS RECEIVABLE, MEDICAL _2

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Tables)	12 Months Ended
	Jun. 30, 2024
Receivables [Abstract]
Schedule of receivables - non current - net	Schedule of receivables - non current - net 2026 $ 631,415 2027 369,429 2028 87,000 2029 87,000 Total $ 1,174,844
Summary of allowance for credit losses	Summary of allowance for credit losses Description Balance Additions(Recovery) (1) Deductions Balance Accounts receivable $ 198,593 $ — $ 32,544 $ 166,049 Management and other fees receivable 12,608,567 (238,646 ) — 12,369,921 Management and other fees receivable - related medical practices 3,989,692 2,120,707 — 6,110,399 Notes receivable 777,354 — — 777,354 Balance Balance Description June 30, 2022 Additions Deductions June 30, 2023 Accounts receivable $ 204,597 $ 55,000 $ 61,004 $ 198,593 Management and other fees receivable 16,627,917 4,007,382 8,026,732 12,608,567 Management and other fees receivable - related medical practices 4,686,893 1,451,094 2,148,295 3,989,692 Notes receivable 777,354 — — 777,354 (1) Included in provision for credit losses.
Schedule of facilities	Schedule of facilities For the Year Ended June 30, 2024 2023 Total Facilities Owned or Managed (at Beginning of Year) 27 27 Facilities Added by: Internal development 1 1 Managed Facilities Closed — (1 ) Total Facilities Owned or Managed (at End of Year) 28 27

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Schedule of inventories As of June 30, 2024 2023 Purchased parts and components $ 2,524,201 $ 2,346,300 Work-in-process 191,240 223,366 Inventories $ 2,715,441 $ 2,569,666

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment, at cost, less accumulated depreciation and amortization	Schedule of property and equipment, at cost, less accumulated depreciation and amortization As of June 30, 2024 2023 Diagnostic equipment $ 33,243,694 $ 33,144,266 Research, development and demonstration equipment 6,199,941 6,199,941 Machinery and equipment 2,069,055 2,069,055 Furniture and fixtures 3,742,169 3,714,499 Leasehold improvements 16,312,904 15,650,041 Building 939,614 939,614 62,507,377 61,717,416 Less: Accumulated depreciation and amortization 43,798,457 39,571,043 $ 18,708,920 $ 22,146,373

OPERATING & FINANCING LEASES (T

OPERATING & FINANCING LEASES (Tables)	12 Months Ended
	Jun. 30, 2024
Operating Financing Leases
Schedule of reconciliation of operating and financing lease payments	Schedule of reconciliation of operating and financing lease payments Year Ending June 30, Operating Lease Payments Financing Lease Payments 2025 $ 5,895,014 $ 244,343 2026 5,561,968 244,343 2027 5,226,352 162,897 2028 5,194,655 — 2029 4,865,285 — Thereafter 29,295,110 — Present value discount (15,096,964 ) (31,074 ) Total lease liability $ 40,941,420 $ 620,509
Schedule of weighted average remaining lease term	Schedule of weighted average remaining lease term Operating leases - years 11.0 Finance lease - years 2.6 Weighted Average Discount Rate Operating leases 6.4 % Finance lease 3.6 %
Schedule of components of lease expense	Schedule of components of lease expense For Year Ended June 30, 2024 2023 Operating lease cost $ 5,685,008 $ 5,887,390 Finance lease cost: Depreciation of leased equipment $ 198,881 $ 198,881 Interest on lease liabilities 26,534 35,833 Total finance lease cost $ 225,415 $ 234,714
Schedule of supplemental cash flow information related to leases	Schedule of supplemental cash flow information related to leases For Year Ended June 30, Cash paid for amounts included in the measurement of lease liabilities: 2024 2023 Operating cash flows from operating leases $ 6,363,561 $ 5,577,578 Financing cash flows from financing leases $ 244,344 $ 244,344 Right-of-use and equipment assets obtained in exchange for lease obligations: Operating leases $ 3,715,138 $ 2,902,584

OTHER INTANGIBLE ASSETS (Tables

OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of other intangible assets, net of accumulated amortization	Schedule of other intangible assets, net of accumulated amortization As of June 30, 2024 2023 Capitalized software development costs $ 7,004,847 $ 7,004,847 Patents and copyrights 5,259,811 5,452,345 Non-competition agreements 4,150,000 4,150,000 Customer relationships 3,900,000 3,900,000 20,314,658 20,507,192 Less: Accumulated amortization 17,444,334 17,075,327 $ 2,870,324 $ 3,431,865
Schedule of other intangible assets	Schedule of other intangible assets Total Patents and Copyrights Customer Relationships 2025 $ 351,882 $ 151,882 $ 200,000 2026 339,179 139,179 200,000 2027 326,502 126,502 200,000 2028 320,232 120,232 200,000 2029 313,052 113,052 200,000 Thereafter 1,219,477 505,310 714,167 Other intangible assets - net $ 2,870,324 $ 1,156,157 $ 1,714,167
Schedule of other intangible assets	Schedule of other intangible assets For the Year-ended June 30, 2024 2023 Balance – Beginning of Year $ 3,431,865 $ 3,703,885 Amounts capitalized 32,885 119,571 Patents written off (225,419 ) — Amortization (369,007 ) (391,591 ) Balance – End of Year $ 2,870,324 $ 3,431,865

CONTROLLING AND NONCONTROLLIN_2

CONTROLLING AND NONCONTROLLING INTERESTS (Tables)	12 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Schedule of HDM members equity	Schedule of HDM members equity June 30, 2024 June 30, 2023 Class A Members Class B Member Class A Members Class B Member Opening Members’ Equity ($ 7,079,293 ) $ 54,781,813 ($ 4,053,833 ) $ 50,292,073 Share of Net Income $ 3,530,021 $ 20,705,681 $ 2,750,740 $ 18,513,540 Buyout of noncontrolling interests — — — — Distributions ($ 5,630,336 ) $ (13,669,664 ) ($ 5,776,200 ) $ (14,023,800 ) Ending Members’ Equity ($ 9,179,608 ) $ 61,817,830 ($ 7,079,293 ) $ 54,781,813

LONG-TERM DEBT, NOTES PAYABLE_2

LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES (Tables)	12 Months Ended
	Jun. 30, 2024
Long-term Debt Notes Payable And Capital Leases
Schedule of long-term debt, notes payable and capital leases	Schedule of long-term debt, notes payable and capital leases 2024 2023 Note payable requiring monthly payments of interest at a rate of 7 240 4,472 October 2026 310,827 $ 113,940 $ 158,842 The revolving credit note was extended to November 14, 2024. The Company can borrow up to $ 10,000,000 8.5 — — 113,940 158,842 Less: Current portion 47,002 43,767 $ 66,938 $ 115,075
Schedule of maturities of long-term debt	Schedule of maturities of long-term debt Years Ending June 30, 2025 $ 47,002 2026 50,448 2027 16,490 Long-Term Debt Over Five Years and Thereafter $ 113,940

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of components of the provision for income taxes	Schedule of components of the provision for income taxes Years Ended June 30, Current: 2024 2023 Federal $ 429,873 $ — State 1,943,588 652,521 Subtotal 2,373,461 652,521 Deferred: Federal deferred taxes 2,585,515 2,770,980 State deferred taxes 209,992 208,570 Subtotal 2,795,507 2,979,550 Provision (Benefit) for Income Taxes - Net $ 5,168,968 $ 3,632,071
Schedule of reconciliation of federal statutory income tax rate to company’s effective tax rate	Schedule of reconciliation of federal statutory income tax rate to company’s effective tax rate Years Ended June 30, 2024 2023 Taxes at federal statutory rate 21.0 % 21.0 % State and local income taxes (benefit), net of federal benefit 7.1 % 5.1 % Non-controlling interest (5.3 )% (4.6 )% Expiration of tax credits 2.2 % 2.8 % Return to provision adjustments — % (2.3 )% Change in the valuation allowance (0.2 )% (0.5 )% Other 2.0 % 1.5 % Effective income tax rate 26.8 % 23.0 %
Schedule of company’s deferred tax assets and liabilities	Schedule of company’s deferred tax assets and liabilities June 30, 2024 2023 Deferred tax assets: Allowance for credit losses $ 3,969,819 $ 3,360,809 Non-deductible accruals 758,700 707,400 Net operating carryforwards 396,092 2,768,844 Tax credits 1,323,018 2,981,214 Capitalized research and development 747,407 369,675 Right of use assets and lease liabilities 114,116 112,938 Inventories 106,879 105,310 Deferred Tax Assets - gross 7,416,031 10,406,190 Valuation allowance (192,776 ) (364,230 ) Total deferred tax assets 7,223,255 10,041,960 Property and equipment and depreciation (267,124 ) (151,007 ) Intangibles (104,436 ) (243,751 ) Total deferred tax liabilities (371,560 ) (394,758 ) Net deferred tax asset $ 6,851,695 $ 9,647,202

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Jun. 30, 2024
Payables and Accruals [Abstract]
Schedule of other current liabilities	Schedule of other current liabilities June 30, 2024 2023 Accrued salaries, commissions and payroll taxes $ 4,677,690 $ 4,413,044 Sales tax payable 197,317 193,041 State income taxes payable 1,461,336 48,353 Legal and other professional fees 11,207 11,207 Accounting fees 119,800 100,000 Self-funded health insurance reserve 121,445 100,971 Accrued interest and penalty 3,534 3,534 Other 1,348,710 573,574 Other current liabilities $ 7,941,039 $ 5,443,724

SEGMENT AND RELATED INFORMATI_2

SEGMENT AND RELATED INFORMATION (Tables)	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of summarized segment financial information	Schedule of summarized segment financial information Manufacturing and Servicing of Medical Management of Diagnostic Imaging Fiscal 2024: Equipment Center Totals Net revenues from external customers $ 8,329,106 $ 94,554,983 $ 102,884,089 Intersegment net revenues * $ 1,073,333 $ — $ 1,073,333 (Loss) Income from operations $ (6,958,012 ) $ 23,493,376 $ 16,535,364 Depreciation and amortization $ 238,802 $ 4,357,619 $ 4,596,421 Total identifiable assets $ 30,360,188 $ 183,885,781 $ 214,245,969 Capital expenditures $ 32,885 $ 789,961 $ 822,846 Fiscal 2023: Net revenues from external customers $ 8,260,711 $ 90,384,390 $ 98,645,101 Intersegment net revenues * $ 985,833 $ — $ 985,833 (Loss) Income from operations $ (5,875,126 ) $ 20,664,388 $ 14,789,262 Depreciation and amortization $ 263,720 $ 4,276,415 $ 4,540,135 Total identifiable assets $ 30,892,807 $ 170,153,612 $ 201,046,419 Capital expenditures $ 119,571 $ 4,218,084 $ 4,337,655 * Amounts eliminated in consolidation
Schedule of export product sales	Schedule of export product sales For the Years Ended June 30 2024 2023 Canada 0.2 % 8.5 % Germany — 4.9 % United Arab Emirates — 0.7 % 0.2 % 14.1 %
Schedule of export service revenues	Schedule of export service revenues For the Years Ended June 30, 2024 2023 Puerto Rico 1.9 % 1.5 % Switzerland 0.3 0.3 Germany 2.0 1.6 England 0.7 0.6 United Arab Emirates 0.3 0.1 Dominican Republic 1.2 0.5 Canada — 0.6 Greece 0.3 0.3 Australia 0.7 0.9 7.4 % 6.4 %

DESCRIPTION OF BUSINESS AND L_2

DESCRIPTION OF BUSINESS AND LIQUIDITY AND CAPITAL RESOURCES (Details Narrative) - Nonconsolidated Investees, Other [Member] - USD ($)	12 Months Ended
	Jun. 30, 2022	Jul. 01, 2015
Interest received percentage		24.20%
Ownership interest percentage	70.80%	45.80%
Non-controlling interests from the minority shareholders	$ 546,000
Noncontrolling Interest [Member]
Ownership interest percentage	29.20%	30%

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Useful Life in Years - (Details)	Jun. 30, 2024
Minimum [Member] | Diagnostic Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Research Deveopment And Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Minimum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	2 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Maximum [Member] | Diagnostic Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	13 years
Maximum [Member] | Research Deveopment And Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Maximum [Member] | Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	9 years
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Weighted Average [Member] | Building [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	28 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disaggregation of Revenue [Line Items]
Net Patient Fee Revenue	$ 33,815,796	$ 29,793,993
Commercial Insurance/ Managed Care [Member]
Disaggregation of Revenue [Line Items]
Net Patient Fee Revenue	4,952,712	4,124,646
Medicare/Medicaid [Member]
Disaggregation of Revenue [Line Items]
Net Patient Fee Revenue	1,138,176	1,063,846
Workers? Compensation/Personal Injury [Member]
Disaggregation of Revenue [Line Items]
Net Patient Fee Revenue	20,673,483	18,670,019
Other [Member]
Disaggregation of Revenue [Line Items]
Net Patient Fee Revenue	$ 7,051,425	$ 5,935,482

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings per share - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Net income available to common stockholders	$ 10,567,396	$ 9,375,776
Weighted average shares outstanding basic	6,350,862	6,539,376
Basic income per common share	$ 1.66	$ 1.43
Common Stock [Member]
Net income available to common stockholders	$ 9,908,920	$ 8,801,974
Weighted average shares outstanding basic	6,350,862	6,539,376
Basic income per common share	$ 1.56	$ 1.35
Weighted average shares outstanding	6,350,862	6,539,376
Class C Common Stock	127,504	127,504
Total Denominator for diluted earnings per share	6,478,366	6,666,880
Diluted income per common share	$ 1.53	$ 1.32
Common Class C [Member]
Net income available to common stockholders	$ 167,700	$ 146,136
Weighted average shares outstanding basic	382,513	382,513
Basic income per common share	$ 0.44	$ 0.38
Weighted average shares outstanding	382,513	382,513
Class C Common Stock	0	0
Total Denominator for diluted earnings per share	382,513	382,513
Diluted income per common share	$ 0.44	$ 0.38

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	12 Months Ended
	Jun. 30, 2024 USD ($) shares	Jun. 30, 2023 USD ($) shares	Jul. 02, 2022 USD ($)
Product Information [Line Items]
Maintenance and repair expenses	$ 2,948,000	$ 2,801,000
Management agreements with company total medical practices	22
Scanners with management agreements with company owned by related party	3
Scanners with management with company located in new york state	19
[custom:ProvisionForBadDebts]	$ 1,882,061	5,513,476
[custom:ManagementFeeReceivableForUnrelatedParties-0]			$ 33,419,219
[custom:ManagementFeeReceivableForRelatedParties-0]			8,602,561
[custom:AccountsReceivableServiceContractsNet-0]			$ 4,335,956
Advertising Expense	731,000	570,000
Penalties	$ 20,444	$ 31,122
Conversion of Class C Common Stock | shares	127,504	127,504
Cash deposit	$ 53,883,000
Federally insured limits	$ 250,000
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Related Parties [Member]
Product Information [Line Items]
Concentration risk, percentage	12%	12%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Related Parties Medical Practices [Member]
Product Information [Line Items]
Concentration risk, percentage	12%	13%
Diagnostic Imaging Facility [Member]
Product Information [Line Items]
Contractual fees for services rendered minimum	$ 84,000
Contractual fees for services rendered maximum	$ 447,000
Intellectual Property [Member]
Product Information [Line Items]
Finite-lived intangible asset, useful life	15 years
Noncompete Agreements [Member]
Product Information [Line Items]
Finite-lived intangible asset, useful life	7 years
Customer Relationships [Member]
Product Information [Line Items]
Finite-lived intangible asset, useful life	20 years

ACCOUNTS RECEIVABLE, MEDICAL _3

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details)	Jun. 30, 2024 USD ($)
Receivables [Abstract]
2026	$ 631,415
2027	369,429
2028	87,000
2029	87,000
Total	$ 1,174,844

ACCOUNTS RECEIVABLE, MEDICAL _4

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Allowance for doubtful accounts (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		$ 198,593	$ 204,597
Additions (Included in provision for bad debts)	[1]	0	55,000
Deductions		32,544	61,004
Ending Balance		166,049	198,593
Management And Other Fees Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		12,608,567	16,627,917
Additions (Included in provision for bad debts)	[1]	(238,646)	4,007,382
Deductions		0	8,026,732
Ending Balance		12,369,921	12,608,567
Management And Other Fees Receivable Related Medical Practices [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		3,989,692	4,686,893
Additions (Included in provision for bad debts)	[1]	2,120,707	1,451,094
Deductions		0	2,148,295
Ending Balance		6,110,399	3,989,692
Notes Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Beginning Balance		777,354	777,354
Additions (Included in provision for bad debts)	[1]	0	0
Deductions		0	0
Ending Balance		$ 777,354	$ 777,354
[1]Included in provision for credit losses.

ACCOUNTS RECEIVABLE, MEDICAL _5

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Total Facilities (Details) - Integer	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Receivables [Abstract]
Total Facilities Owned or Managed (at Beginning of Year)	27	27
Internal development	1	1
Managed Facilities Closed	0	(1)
Total Facilities Owned or Managed (at End of Year)	28	27

ACCOUNTS RECEIVABLE, MEDICAL _6

ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Receivables [Abstract]
Long term accounts receivable balances	$ 829,473	$ 710,085
Percentage of consolidated net revenue from management fees	12%	12%

INVENTORIES - Inventories (Deta

INVENTORIES - Inventories (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Purchased parts and components	$ 2,524,201	$ 2,346,300
Work-in-process	191,240	223,366
Inventories	$ 2,715,441	$ 2,569,666

PROPERTY AND EQUIPMENT - Proper

PROPERTY AND EQUIPMENT - Property and equipment (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 62,507,377	$ 61,717,416
Less: Accumulated depreciation and amortization	43,798,457	39,571,043
Property plant and equipment, net	18,708,920	22,146,373
Diagnostic Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	33,243,694	33,144,266
Research, development and demonstration equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	6,199,941	6,199,941
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	2,069,055	2,069,055
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	3,742,169	3,714,499
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	16,312,904	15,650,041
Building [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment, gross	$ 939,614	$ 939,614

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation and amortization of property and equipment	$ 4,227,414	$ 4,148,544

OPERATING & FINANCING LEASES -

OPERATING & FINANCING LEASES - Lease payments (Details)	Jun. 30, 2024 USD ($)
Operating Lease Payments [Member]
2025	$ 5,895,014
2026	5,561,968
2027	5,226,352
2028	5,194,655
2029	4,865,285
Thereafter	29,295,110
Present value discount	(15,096,964)
Total lease liability	40,941,420
Financing Lease Payments [Member]
2025	244,343
2026	244,343
2027	162,897
2028	0
2029	0
Thereafter	0
Present value discount	(31,074)
Total lease liability	$ 620,509

OPERATING & FINANCING LEASES _2

OPERATING & FINANCING LEASES - Weighted average remaining lease term (Details)	Jun. 30, 2024
Operating Financing Leases
Operating leases - years	11 years
Finance lease - years	2 years 7 months 6 days
Weighted average discount rate, operating leases	6.40%
Weighted average discount rate, finance leases	3.60%

OPERATING & FINANCING LEASES _3

OPERATING & FINANCING LEASES - Components of lease expense (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Financing Leases
Operating lease cost	$ 5,685,008	$ 5,887,390
Finance lease cost:
Depreciation of leased equipment	198,881	198,881
Interest on lease liabilities	26,534	35,833
Total finance lease cost	$ 225,415	$ 234,714

OPERATING & FINANCING LEASES _4

OPERATING & FINANCING LEASES - Related to leases (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Financing Leases
Operating cash flows from operating leases	$ 6,363,561	$ 5,577,578
Financing cash flows from financing leases	244,344	244,344
Right-of-use and equipment assets obtained in exchange for lease obligations:
Operating leases	$ 3,715,138	$ 2,902,584

OTHER INTANGIBLE ASSETS - Other

OTHER INTANGIBLE ASSETS - Other intangible assets net of amortization (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	$ 20,314,658	$ 20,507,192
Less: Accumulated amortization	17,444,334	17,075,327
Other intangible assets-net	2,870,324	3,431,865
Software and Software Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	7,004,847	7,004,847
Patents and copyrights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	5,259,811	5,452,345
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	4,150,000	4,150,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross other intangible assets	$ 3,900,000	$ 3,900,000

OTHER INTANGIBLE ASSETS - Sched

OTHER INTANGIBLE ASSETS - Schedule of other intangible assets - (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
2025	$ 351,882
2026	339,179
2027	326,502
2028	320,232
2029	313,052
Thereafter	1,219,477
Other intangible assets - net	2,870,324	$ 3,431,865
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
2025	151,882
2026	139,179
2027	126,502
2028	120,232
2029	113,052
Thereafter	505,310
Other intangible assets - net	1,156,157
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
2025	200,000
2026	200,000
2027	200,000
2028	200,000
2029	200,000
Thereafter	714,167
Other intangible assets - net	$ 1,714,167

OTHER INTANGIBLE ASSETS - Intan

OTHER INTANGIBLE ASSETS - Intangle assets - (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Balance - Beginning of Year	$ 3,431,865	$ 3,703,885
Amounts capitalized	32,885	119,571
Patents written off	(225,419)	0
Amortization	(369,007)	(391,591)
Balance - End of Year	$ 2,870,324	$ 3,431,865

OTHER INTANGIBLE ASSETS (Detail

OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization period for other intangible assets	9 years 10 months 24 days
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of customer relationships	$ 169,007	$ 191,591
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization of customer relationships	$ 200,000	$ 200,000

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - USD ($)		12 Months Ended
	Sep. 26, 2022	Jun. 30, 2024	Jun. 30, 2023	Aug. 10, 2010	Apr. 23, 2010
Payments for repurchase of equity		$ 2,505,832	$ 1,759,457
Purchase of treasury shares		156,206	103,148
Purchase of treasury stock		$ 2,505,832	$ 1,759,457
Cancellation of treasury shares		122,588	103,328
Cancellation of treasury stock		$ 2,005,020	$ 1,919,027
Board of Directors Chairman [Member]
Payments for repurchase of equity	$ 9,000,000
N 2010 Stock Bonus Plan [Member]
Common stock, capital shares reserved for future issuance					2,000,000
Shares registered				2,000,000
Number of shares available for future grant		450,177
Number of shares were issued		0	0
Common Stock [Member]
Dividends payable, nature		Cash dividends payable on the common stock shall, in all cases, be on a per share basis, one hundred twenty percent (120%) of the cash dividend payable on shares of Class B common stock and three hundred sixty percent (360%) of the cash dividend payable on a share of Class C common stock.
Conversuion of shares into one-for-one basis		Class C common stock is convertible into shares of common stock on a three-for-one basis.
Common stock, voting rights		one vote per share for the common stock.
Common stock, shares outstanding		6,328,294	6,450,882
Common Class B [Member]
Conversuion of shares into one-for-one basis		Class B common stock is convertible into shares of common stock on a one-for-one basis.
Common stock, voting rights		Class B common stock has 10 votes per share.
Common stock, shares outstanding		146	146
Common Class C [Member]
Conversuion of shares into one-for-one basis		The Class C common stock was offered on a three-for-one basis to the holders of the Class B common stock.
Common stock, voting rights		The Class C common stock has 25 votes per share
Common stock, shares outstanding		382,513	382,513
Preferred Class A [Member]
Dividends payable, nature		The stock dividend was payable to holders of common stock on October 20, 1995. Class A non-voting preferred stock issued pursuant to such stock dividend approximates 313,000 shares.
Common stock, voting rights		one share of Class A non-voting preferred stock for every five shares of common stock.

CONTROLLING AND NONCONTROLLIN_3

CONTROLLING AND NONCONTROLLING INTERESTS - HDM members equity (Details) - HDM Equity [Member] - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Common Class A [Member]
Noncontrolling Interest [Line Items]
Opening Members Equity	$ 7,079,293	$ 4,053,833
Share of Net Income	3,530,021	2,750,740
Buyout of noncontrolling interests	0	0
Distributions	5,630,336	5,776,200
Ending Members Equity	9,179,608	7,079,293
Common Class B [Member]
Noncontrolling Interest [Line Items]
Opening Members Equity	54,781,813	50,292,073
Share of Net Income	20,705,681	18,513,540
Buyout of noncontrolling interests	0	0
Distributions	(13,669,664)	(14,023,800)
Ending Members Equity	$ 61,817,830	$ 54,781,813

CONTROLLING AND NONCONTROLLIN_4

CONTROLLING AND NONCONTROLLING INTERESTS (Details Narrative) - HDM [Member]			12 Months Ended
	Jan. 08, 2015 USD ($)	Feb. 13, 2013 USD ($)	Jun. 30, 2023 USD ($)	Mar. 05, 2013 USD ($) Integer
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Purchase of stand up MRI centers | Integer				12
Purchase of other MRI centers | Integer				2
HDM purchase price includes consideration to outside investors				$ 1,500,000
HDM purchase from Health Diagnostics (HD) ($)				35,900,000
HDM entered agreement for consulting and non-competition agreement ($)				$ 4,100,000
Class B Controlling Interests [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership interest of company		50.50%
Company contribution		$ 20,200,000
Class A Controlling Interests [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership interest of company	60.40%		70.80%
Purchase of interests from Class A, percentage	20%
Purchase of interests from Class A	$ 4,971,094		$ 546,000
Class A Controlling Interests [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Ownership interest of investors		49.50%	29.20%
Investors contribution		$ 19,800,000

LONG-TERM DEBT, NOTES PAYABLE_3

LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES - (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Debt Instrument [Line Items]
Long term debt, notes payable and capital leases	$ 113,940	$ 158,842
Current portion of long term debt, notes payable and capital leases	47,002	43,767
Long term debt, notes payable and capital leases less current portion	66,938	115,075
Note Payable 1 [Member]
Debt Instrument [Line Items]
Long term debt, notes payable and capital leases	113,940	158,842
Note Payable 2 [Member]
Debt Instrument [Line Items]
Long term debt, notes payable and capital leases	$ 0	$ 0

LONG-TERM DEBT, NOTES PAYABLE_4

LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES - Maturities of long term debt over 5 years - (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Long-term Debt Notes Payable And Capital Leases
2024	$ 47,002
2025	50,448
2026	16,490
Total long term debt	$ 113,940	$ 158,842

LONG-TERM DEBT, NOTES PAYABLE_5

LONG-TERM DEBT, NOTES PAYABLE AND CAPITAL LEASES (Details Narrative)	12 Months Ended
	Jun. 30, 2024 USD ($)
Note Payable 1 [Member]
Debt Instrument [Line Items]
Interest rate	7%
Monthly payment period	240 months
Debt instrument, periodic payment	$ 4,472
Maturity date	October 2026
Book value of building	$ 310,827
Note Payable 2 [Member]
Debt Instrument [Line Items]
Interest rate	8.50%
Proceeds from lines of credit	$ 10,000,000

INCOME TAXES - Components of pr

INCOME TAXES - Components of provision for income taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Current:
Federal	$ 429,873	$ 0
State	1,943,588	652,521
Subtotal	2,373,461	652,521
Deferred:
Federal deferred taxes	2,585,515	2,770,980
State deferred taxes	209,992	208,570
Subtotal	2,795,507	2,979,550
Provision (Benefit) for Income Taxes - Net	$ 5,168,968	$ 3,632,071

INCOME TAXES - Reconciliation o

INCOME TAXES - Reconciliation of federal statutory income tax rate (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Taxes at federal statutory rate	21%	21%
State and local income taxes (benefit), net of federal benefit	7.10%	5.10%
Noncontrolling interest	(5.30%)	(4.60%)
Expiration of tax credits	2.20%	2.80%
Return to provision adjustments	0%	(2.30%)
Change in the valuation allowance	(0.20%)	(0.50%)
Other	2%	1.50%
Effective income tax rate	26.80%	23%

INCOME TAXES - Deferred tax ass

INCOME TAXES - Deferred tax assets and liabilities - (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Deferred tax assets:
Allowance for credit losses	$ 3,969,819	$ 3,360,809
Non-deductible accruals	758,700	707,400
Net operating carryforwards	396,092	2,768,844
Tax credits	1,323,018	2,981,214
Capitalized research and development	747,407	369,675
Right of use assets and lease liabilities	114,116	112,938
Inventories	106,879	105,310
Deferred Tax Assets - gross	7,416,031	10,406,190
Valuation allowance	(192,776)	(364,230)
Total deferred tax assets	7,223,255	10,041,960
Property and equipment and depreciation	(267,124)	(151,007)
Intangibles	(104,436)	(243,751)
Total deferred tax liabilities	(371,560)	(394,758)
Net deferred tax asset	$ 6,851,695	$ 9,647,202

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 7,223,255	$ 10,041,960
Deferred tax liability	371,560
Allowance for doubtful accounts and tax credits	1,323,000
State operating loss carryforwards	4,516,000
City operating loss carryforwards	618,000
Valuation allowance of state operating losses	$ 2,746,000
Percentage of excise tax	1%
Corporate alternative minimum tax percentage	15%
Valuation allowance for deferred tax assets	$ 171,000	$ 78,000
Tax credits carryforwards	$ 1,323,000

OTHER CURRENT LIABILITIES - Oth

OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Payables and Accruals [Abstract]
Accrued salaries, commissions and payroll taxes	$ 4,677,690	$ 4,413,044
Sales tax payable	197,317	193,041
State income taxes payable	1,461,336	48,353
Legal and other professional fees	11,207	11,207
Accounting fees	119,800	100,000
Self-funded health insurance reserve	121,445	100,971
Accrued interest and penalty	3,534	3,534
Other	1,348,710	573,574
Other current liabilities	$ 7,941,039	$ 5,443,724

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)		12 Months Ended
	Feb. 29, 2016	Jun. 30, 2024	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Rent expense for operating leases		$ 5,685,000	$ 5,887,000
Property tax abatement from suffolk county IDA	50%
Property tax abatement	$ 440,000
Employer contributions		0	36,523
Liability for individual claims		110,000
Reserve for self-funded		$ 121,000	$ 101,000

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Interest paid	$ 76,997	$ 50,132
Income taxes paid	$ 507,139	$ 1,439,507

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		12 Months Ended
	Jun. 01, 2017	Jun. 30, 2024	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Monthly fee	$ 23,884
Bensonhurst MRI Limited Partnership [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party transaction, description		Bensonhurst MRI Limited Partnership (“Bensonhurst”), in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance of its Upright MRI Scanner for a price of $110,000 per annum. On February 1, 2024, Bensonhurst entered into a second contract with the Company for the service and maintenance of a High-Field MRI Scanner for a price of $70,000 per annum. Also, during fiscal year ended June 30, 2024, the Company charged Bensonhurst MRI Limited Partnership $190,362 for reimbursable salaries and marketing expenses.
Radian Healthcare Management LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party transaction, description		Radian Healthcare Management, LLC (“Radian”), which is owned by the son-in-law of the CEO and President of the Company provided the Company with personnel recruitment of 32 new employees at a fee of approximately $200,000 during the fiscal year ended June 30, 2024.
Magnetic Resonance Management [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of price of the equipment			$ 576,857
Bears interest rate			9%
Gain on sale of equipments			$ 576,857

SEGMENT AND RELATED INFORMATI_3

SEGMENT AND RELATED INFORMATION - Summarized segments - (Details) - USD ($)		12 Months Ended
		Jun. 30, 2024	Jun. 30, 2023
Revenue from External Customer [Line Items]
Net revenues from external customers		$ 102,884,089	$ 98,645,101
Inter-segment net revenues	[1]	1,073,333	985,833
(Loss) Income from operations		16,535,364	14,789,262
Depreciation and amortization		4,596,421	4,540,135
Total identifiable assets		214,245,969	201,046,419
Capital expenditures		822,846	4,337,655
Manufacturing and Servicing of Medical Equipment [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers		8,329,106	8,260,711
Inter-segment net revenues	[1]	1,073,333	985,833
(Loss) Income from operations		(6,958,012)	(5,875,126)
Depreciation and amortization		238,802	263,720
Total identifiable assets		30,360,188	30,892,807
Capital expenditures		32,885	119,571
Management of Diagnostic Imaging Center [Member]
Revenue from External Customer [Line Items]
Net revenues from external customers		94,554,983	90,384,390
Inter-segment net revenues	[1]	0	0
(Loss) Income from operations		23,493,376	20,664,388
Depreciation and amortization		4,357,619	4,276,415
Total identifiable assets		183,885,781	170,153,612
Capital expenditures		$ 789,961	$ 4,218,084
[1]Amounts eliminated in consolidation

SEGMENT AND RELATED INFORMATI_4

SEGMENT AND RELATED INFORMATION - Foreign product sales - (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign product sales	0.20%	14.10%
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign product sales	0.20%	8.50%
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign product sales	0%	4.90%
UNITED ARAB EMIRATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign product sales	0%	0.70%

SEGMENT AND RELATED INFORMATI_5

SEGMENT AND RELATED INFORMATION - Foreign service and repair fees - (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	7.40%	6.40%
PUERTO RICO
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	1.90%	1.50%
SWITZERLAND
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0.30%	0.30%
GERMANY
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	2%	1.60%
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0.70%	0.60%
UNITED ARAB EMIRATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0.30%	0.10%
DOMINICAN REPUBLIC
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	1.20%	0.50%
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0%	0.60%
GREECE
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0.30%	0.30%
AUSTRALIA
Revenues from External Customers and Long-Lived Assets [Line Items]
Foreign service and repair fees	0.70%	0.90%

SEGMENT AND RELATED INFORMATI_6

SEGMENT AND RELATED INFORMATION (Details Narrative)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting [Abstract]
Export sales of medical equipment percentage	0.20%	14.10%
Percentage of service and repair of medical equipment	7.40%	6.40%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]	Sep. 18, 2024 USD ($) shares
Subsequent Event [Line Items]
Number of shares repurchased, shares | shares	19,914
Number of shares repurchased, value | $	$ 340,933